Nabi, FDA agree on SPA for NicVAx

Nabi Biopharmaceuticals and the FDA have reached an agreement on a Special Protocol Assessment (SPA) for a Phase II trial of NicVAX, the company's anti-smoking vaccine. An SPA is a process by which sponsors and the FDA reach agreement on the design and size of clinical trials.

"This SPA provides us with a clear, well-defined path to support approval of NicVAX and further strengthens our leadership position to bring the first smoking cessation vaccine to market," said Dr. Raafat Fahim, President and CEO of Nabi. "Ideally, we would prefer to initiate Phase III testing with a strategic partner and we continue to pursue all options through our strategic alternatives process. The SPA further reduces the regulatory risks associated with the NicVAX program for both Nabi and its potential partners.

- here's Nabi's release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.